ViiV’s injection still suppresses HIV when taken every two months – studyGSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus Share XViiV’s injection still suppresses HIV when taken every two months – studyhttps://pharmaphorum.com/news/viivs-injection-still-suppresses-hiv-when-taken-every-two-months-study/
Gilead will challenge US government patent on PrEP drug TruvadaGilead Sciences has said it plans to challenge patents held by the US government on the use of Share XGilead will challenge US government patent on PrEP drug Truvadahttps://pharmaphorum.com/news/gilead-will-challenge-us-government-patent-on-prep-drug-truvada/
Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
FDA reviewer backs Gilead’s Descovy for PrEP, but not in womenGilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory Share XFDA reviewer backs Gilead’s Descovy for PrEP, but not in womenhttps://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/
Gilead ups forecasts as new HIV drug boosts salesGilead has become the latest pharma company to raise its full year sales forecasts following stronger than expected Share XGilead ups forecasts as new HIV drug boosts saleshttps://pharmaphorum.com/news/gilead-ups-sales-forecasts-as-new-hiv-drug-boosts-sales/
ViiV files monthly HIV jab in EuropeViiV Healthcare has submitted its once-monthly two-drug injectable therapy for HIV to the EMA, setting up possible approval Share XViiV files monthly HIV jab in Europehttps://pharmaphorum.com/news/viiv-files-monthly-hiv-jab-in-europe/
ViiV’s first-in-class HIV drug on course for filings this yearViiV Healthcare has new data on its first-in-class HIV drug fostemsavir that back up its long-term effects, and Share XViiV’s first-in-class HIV drug on course for filings this yearhttps://pharmaphorum.com/news/viivs-first-in-class-hiv-drug-on-course-for-filings-this-year/
The importance of pharma CSRThe industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Share XThe importance of pharma CSRhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-importance-of-pharma-csr/
ViiV hails data showing switch from Truvada to two-drug HIV regimenViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors Share XViiV hails data showing switch from Truvada to two-drug HIV regimenhttps://pharmaphorum.com/news/viiv-hails-data-showing-switch-from-truvada-to-two-drug-hiv-regimen/
